Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Marinus Pharma CS
(NQ:
MRNS
)
1.840
+0.110 (+6.36%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Marinus Pharma CS
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder
September 20, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 09, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder
August 26, 2021
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
August 18, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
August 25, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 18, 2021
Gainers PharmaCyte Biotech (NASDAQ:PMCB) shares rose 119.0% to $7.49 during Wednesday's regular session. Trading volume for PharmaCyte Biotech's stock is 144.3...
Via
Benzinga
Marinus' Oral Ganaxolone Lowers Seizure Frequency In Genetic Disorder
August 18, 2021
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) announced topline data from its open-label Phase 2 trial evaluating oral ganaxolone in patients with seizures associated with...
Via
Benzinga
Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation
August 17, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Earnings Scheduled For August 10, 2021
August 10, 2021
Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter. • Fulcrum Therapeutics (NASDAQ:...
Via
Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
August 08, 2021
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
August 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (...
Via
Benzinga
Exposures
COVID-19
Marinus Pharmaceuticals: Q2 Earnings Insights
August 10, 2021
Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share fell 306.25% over the past year...
Via
Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
August 10, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021
August 03, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Files US Application For Ganaxolone For Genetic Epilepsy, Inks European Commercialization Pact With Orion
August 03, 2021
Marinus Pharmaceuticals Inc (NASDAQ: MRNS) has submitted a marketing application to the FDA seeking approval for its lead product candidate, ganaxolone, to treat...
Via
Benzinga
Exposures
Product Safety
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
August 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (...
Via
Benzinga
Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone
August 03, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update
August 03, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
August 01, 2021
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results....
Via
Benzinga
Exposures
Product Safety
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D.
July 01, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 22, 2021
From
Marinus Pharmaceuticals, Inc.
Via
Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 14, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
June 11, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals: Q1 Earnings Insights
May 17, 2021
Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) were unchanged after the company reported Q1 results. Quarterly Results Earnings per share decreased 131.25% over the past...
Via
Benzinga
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
May 17, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call
May 13, 2021
From
Marinus Pharmaceuticals
Via
Business Wire
Earnings Scheduled For May 17, 2021
May 17, 2021
Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter. • U.S. Well Services (NASDAQ:...
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
May 13, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc...
Via
Benzinga
Exposures
COVID-19
Earnings Scheduled For May 13, 2021
May 13, 2021
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.